Compare Neurocrine Biosciences Inc (NBIX) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nuvalent Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| NBIX | NUVL | |
|---|---|---|
Market Cap | $17.40B | $9.81B |
Sector | Health | Technology |
52-Week High | $180.55 | $123.96 |
52-Week Low | $123.10 | $72.16 |
Enterprise Value | $16.49B | $8.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
